A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory…

Overview of attention for article published in Clinical Cancer Research, August 2004

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (71st percentile)
Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

patent: 13 patents

Readers on

mendeley: 23 Mendeley

So far, Altmetric has seen 13 patents that reference this research output.

Targeting PAX2 for the treatment of breast cancer

Grant US-11033628-B1

United States of America

15 Jun 2021

Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy

Grant US-8735365-B2

United States of America

27 May 2014

Targeting PAX2 for the treatment of breast cancer

Grant US-8653021-B2

United States of America

18 Feb 2014

Targeting PAX2 for the treatment of breast cancer

Grant US-8633149-B2

United States of America

21 Jan 2014

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 9 additional patents.